Congenica is a UK company founded on pioneering research from the Wellcome Trust Sanger Institute, NHS clinicians and regional genetic testing laboratories.
|Telephone:||+44 (0)1223 499 965|
|Address:||BioData Innovation Centre, Wellcome Genome Campus, Hinxton|
|Membership type:||Corporate 51+ (£1,000+VAT pa)|
Headquartered at the Wellcome Genome Campus, Cambridge, U.K., Sapientia’s underlying technology was spun out of the pioneering research from the Sanger Institute and the platform continues to evolve by the well-renowned scientific staff and advisers.
Congenica, the global diagnostic decision support platform provider, today announced a key partnership with the UK’s Epilepsy Society to study the genomics of sudden unexpected death in epilepsy (SUDEP).
23 October 2018Read in full
Genomics England names Congenica as its Clinical Decision Support Service partner for the delivery of the NHS Genomic Medicine Service.
17 October 2018Read in full
Congenica, the global diagnostic decision support platform provider, announced it has entered into an agreement with a new strategic partner, Digital China Health Technologies Cooperation Limited (DCHealth), further extending Congenica’s commitment to the Chinese market.
18 September 2018Read in full
Congenica, the global provider of clinical genomics interpretation software, today announced the appointment of Mrs Wendy Britten as its new Chief Financial Officer (CFO), effective 1st September, 2018. Mrs Britten will have overall control and responsibility for all financial aspects of the business and will play a key role in business development and fundraising activities.
28 August 2018Read in full
Congenica, a global provider of clinical genomics interpretation software, announced today that it has received certification in ISO 13485:2016, a quality management system for medical devices that supports comprehensive policies and processes across the entire business.
28 February 2018Read in full
New software to deliver faster and more accurate diagnoses in genetic epilepsies is the ambition of a ground-breaking partnership between Congenica, a global provider of clinical genomics interpretation software, and FutureNeuro, the SFI Research Centre for Chronic and Rare Neurological Diseases, supported by Science Foundation Ireland.
12 February 2018Read in full
Today Congenica, the global provider of clinical genomics interpretation software, signed a series of significant memorandums of understanding (MOUs) with leading Chinese companies and healthcare providers at a UK-Chinese Future of Medicine trade event in Beijing, China. The meeting was held in conjunction with the State visit of Prime Minister May.
1 February 2018Read in full
Congenica, a global provider of clinical genomics interpretation software, today announced the appointment of its new Chief Executive Officer, David Atkins, PhD. Based at the Company’s headquarters in Cambridge, Dr Atkins also joins Congenica’s Board of Directors.
25 January 2018Read in full
Congenica, a global provider of clinical genomics interpretation software, today announced a new customer partnership with the Coimbra Paediatric Hospital (CPH), a leading paediatric hospital in Portugal and part of the Coimbra Hospital and University Centre (CHUC).
6 September 2017Read in full
Congenica’s Sapientia™ clinical genome analysis software platform will be used by China-based UniteGen to carry out whole genome sequencing (WGS) processing and analysis as part of China’s “100K Wellness Pioneer Project”, hosted by Beijing 4P Health Research Institute.
22 June 2017Read in full